Victoza® significantly reduces the risk of major adverse cardiovascular events in the LEADER trial
Novo Nordisk has announced the top-line results from the LEADER trial, which investigated the cardiovascular safety of Victoza® (liraglutide) over a period of up to 5 years in more than 9,000 adults with type 2 diabetes at high risk of major adverse cardiovascular events.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Novo Nordisk Business and Industry Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Pharmaceuticals | Victoza